Current immune therapeutic strategies in advanced or metastatic non-small cell lung cancer.
10.1097/CM9.0000000000002536
- Author:
Jing XU
1
;
Caixia LIU
1
;
Xiaonan WU
2
;
Jie MA
1
Author Information
1. Center of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
2. Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Lung Neoplasms/drug therapy*;
Immunotherapy
- From:
Chinese Medical Journal
2023;136(15):1765-1782
- CountryChina
- Language:English
-
Abstract:
Immune escape mechanisms in non-small cell lung cancer (NSCLC) can disrupt every step of the anti-cancer immune response. In recent years, an increased understanding of the specific mechanisms fueling immune escape has allowed for the development of numerous immunotherapeutic treatments that have been introduced into the clinical practice. The advent of immunotherapy has dramatically changed the current treatment landscape of advanced or metastatic NSCLC because of its durable efficacy and manageable toxicity. In this review, we will first present a brief overview of recent evidence on immune escape mechanisms in NSCLC. We will then discuss the current promising immunotherapeutic strategies in advanced or metastatic NSCLC tumors.
